Sage Therapeutics this morning offered no update regarding the path forward for SAGE-217, Piper Sandler analyst Danielle Brill tells investors in a post-earnings research note. Management is staying tight-lipped on potential options and gave no indication on whether the FDA meeting has yet occurred, the analyst adds. Although SAGE-217 remains the top focus, Brill thinks Sage's early pipeline is "becoming more interesting." She notes that both SAGE-324 and SAGE-718 will be evaluated in Phase 2 clinical proof-of-concept studies this year. As expected, the Zulresso ramp continues to be slow, the analyst says. Brill still believes SAGE-217's development will ultimately be successful and she maintains an Overweight rating on Sage Therapeutics with a $125 price target. The stock in morning trading is down 16.5% to $53.14.